News

Public · Published

Corcept Reports Positive Results From Phase 2 Bella Trial Of Lifyorli® Combined With NAB-Paclitaxel And Bevacizumab In Patients With Platinum-Resistant Ovarian Cancer

Corcept Therapeutics reported positive results from its Phase 2 Bella trial of Lifyorli combined with nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer. The trial showed 88% of patients alive at the 6-month overall survival timepoint, a median progression-free survival of 7.2 months, and no new safety signals.

Published:

Updated:

What happened

Corcept Therapeutics reported positive results from its Phase 2 Bella trial of Lifyorli combined with nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer. The trial showed 88% of patients alive at the 6-month overall survival timepoint, a median progression-free survival of 7.2 months, and no new safety signals.

Confirmed

Global impact / market context

Positive trial results can raise expectations for future revenue if Lifyorli wins broader approval, because doctors may prescribe it to more patients. For investors, this shifts attention to regulatory steps and launch costs rather than near-term sales, since the trial is mid-stage.

Analyst inference

Corcept is known mainly for its cortisol-related medicines, so success in ovarian cancer would diversify its revenue base. Still, this is a Phase 2 result, which is an earlier-stage study, so approval and commercial launch remain uncertain and could require added capital spending.

Analyst inference

What to watch

  1. Corcept reported no new safety signals in the Bella trial, so any later update that changes this safety profile would be important for the combined Lifyorli, nab-paclitaxel and bevacizumab regimen. Confirmed
  2. Watch whether Corcept says it will discuss these Phase 2 data with regulators about a next-stage trial, which would clarify the timeline and cost needed to move toward approval. Proposed
  3. Track Corcept's research spending and cash available in coming quarters, since advancing Lifyorli in ovarian cancer would likely raise costs before any product revenue arrives. Analyst inference

Evidence

  • Original source link unavailable